Merck and University of Nairobi to Start Medical Oncology Fellowship Program
“We are committed to improving patient’s access to healthcare all over the world”, said Rasha Kelej, who as Chief Social Officer of the healthcare business sector of Merck leads the implementation and coordination of activities, designed to have a positive impact on societies in developing countries. “In Africa, where the number of oncologists is very limited, this starts by building additional medical capacity. Our new program aims to increase the number of qualified oncologists across the continent. The scarcity of trained healthcare personnel capable of tackling prevention, early diagnosis and management of cancer is a bigger challenge in Africa than the lack of financial resources. Therefore we firmly believe that initiatives like ours are very helpful for Africa and also in a further step for more developing countries.”
Merck over the past years has significantly stepped up its activities on the African continent with an expected doubling of sales by 2020. In addition to its cancer drug Erbitux, which made Merck is a pioneer in targeted cancer therapy, the company is also making fast progress in the field of immuno-oncology, aimed at mobilizing the body’s own immune system to fight cancer.
Комментарии